Rui Meng

机构：Guangxi University, Chinese Research Academy of Environmental Sciences · ORCID：0000-0002-6463-9255

发表论文 167 篇 · 总被引 2521 次 · h-index 28

代表论文

• Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study (2025 · The Lancet Oncology · 被引 49)
• Immunomodulatory hydrogel patches loaded with curcumin and tannic acid assembled nanoparticles for radiation dermatitis repair and radioprotection (2024 · Chemical Engineering Journal · 被引 33)
• First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives (2024 · Cancer Biology & Therapy · 被引 10)
• First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 7)
• Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration (2025 · Cancer Biology and Medicine · 被引 7)
• Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial (2024 · Journal of Thoracic Oncology · 被引 7)